NCT04931849

Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

A Pilot Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if using avatrombopag in patients with thrombocytopenia due to temozolomide treatment can safely improve a patient's platelet count and allow the patient to complete the temozolomide treatment course as planned.

Detailed description

The purpose of this study is to determine if using avatrombopag in patients with low platelet count due to temozolomide treatment is safe, while at the same time assess whether the avatrombopag can improve the low platelet count and allow the temozolomide treatment to continue as planned.

Conditions

• Thrombocytopenia

Interventions

Type	Name	Description
DRUG	Avatrombopag	Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)

Timeline

• Start date: 2022-05-06
• Primary completion: 2023-10-11
• Completion: 2024-07-18
• First posted: 2021-06-18
• Last updated: 2025-01-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study